Voyager Therapeutics, Inc.
VYGR
$3.16
$0.030.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -68.00% | 3.40% | -26.22% | -37.58% | 511.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.00% | 3.40% | -26.22% | -37.58% | 511.18% |
| Cost of Revenue | 38.19% | 45.17% | 52.02% | 54.96% | 51.69% |
| Gross Profit | -130.01% | -40.28% | -74.59% | -85.41% | 894.82% |
| SG&A Expenses | 0.27% | 9.18% | 12.59% | 9.43% | 15.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.57% | 34.52% | 39.88% | 39.83% | 39.51% |
| Operating Income | -168.26% | -79.08% | -107.62% | -118.26% | 340.01% |
| Income Before Tax | -148.11% | -49.38% | -89.95% | -102.33% | 388.28% |
| Income Tax Expenses | -52.77% | 50.00% | -12.32% | -0.28% | 8,700.00% |
| Earnings from Continuing Operations | -149.12% | -50.52% | -90.58% | -103.08% | 385.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -149.12% | -50.52% | -90.58% | -103.08% | 385.14% |
| EBIT | -168.26% | -79.08% | -107.62% | -118.26% | 340.01% |
| EBITDA | -162.12% | -70.14% | -101.95% | -112.77% | 383.23% |
| EPS Basic | -134.79% | -43.86% | -86.70% | -100.71% | 366.44% |
| Normalized Basic EPS | -134.08% | -43.02% | -85.76% | -100.03% | 354.99% |
| EPS Diluted | -136.79% | -41.55% | -87.47% | -102.06% | 351.84% |
| Normalized Diluted EPS | -135.64% | -40.45% | -86.40% | -101.45% | 341.88% |
| Average Basic Shares Outstanding | 34.11% | 30.08% | 25.73% | 20.84% | 12.12% |
| Average Diluted Shares Outstanding | 32.09% | 29.55% | 24.41% | 19.55% | 13.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |